EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Reduced chemokine C‐C motif ligand 1 expression may negatively regulate colorectal cancer progression at liver metastatic sites

Miku Iwata, Ryuma Haraguchi, Riko Kitazawa, Chihiro Ito, Kohei Ogawa, Yasutsugu Takada, Sohei Kitazawa iD

Journal of Cellular and Molecular Medicine · 2024

DOI: 10.1111/jcmm.18193 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Cellular and Molecular Medicine, 2024. Verfasst von Miku Iwata und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Molecular Pathology, Ehime University Graduate School of Medicine, Toon City, Ehime, Japan. Hauptthemen laut MEDLINE: Liver, Colorectal Neoplasms. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Colorectal cancer (CRC) liver metastasis, albeit a stage‐IV disease, is completely curable by surgical resection in selected patients. In addressing the molecular basics of this phenomenon, differentially expressed genes at primary and liver metastatic sites were screened by RNA sequencing with the use of paraffin‐embedded surgical specimens. Chemokine C‐C motif ligand 1 (CCL1), a chemotactic factor for a ligand of the chemokine C‐C motif receptor 8 (CCR8), was isolated as one of the differentially expressed genes. Histological analysis revealed that the number of CCL1‐positive cells, mainly tumour associated macrophages (TAMs) located in the stroma of CRC, decreased significantly at liver metastatic sites, while the expression level of CCR8 on CRC remained unchanged. To explore the biological significance of the CCL1‐CCR8 axis in CRC, CCR8‐positive CRC cell line Colo320DM was used to assess the effect of the CCL1‐CCR8 axis on major signalling pathways, epithelial mesenchymal transition induction and cell motility. Upon stimulation of recombinant CCL1 (rCCL1), phosphorylation of AKT was observed in Colo320DM cells; on the other hand, the corresponding significant increase in MMP‐2 levels demonstrated by RT‐qPCR was nullified by siRNA (siCCR8). In the scratch test, rCCL1 treatment significantly increased the motility of Colo320DM cells, which was similarly nullified by siCCR8. Thus, the activation of the CCL1‐CCR8 axis is a positive regulator of CRC tumour progression. Reduced CCL1 expression of TAMs at liver metastatic sites may partly explain the unique slow tumour progression of CRC, thus providing for a grace period for radical resection of metastatic lesions.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

LiverColorectal NeoplasmsHumansChemokine CCL1LigandsChemokinesReceptors, Chemokine

Stichwörter der Autor:innen

CCL1CCR8CRCCRLMTAM

Substanzen

Chemokine CCL1LigandsChemokinesReceptors, Chemokine

Autor:innen und Institutionen

  • Department of Molecular Pathology, Ehime University Graduate School of Medicine, Toon City, Ehime, Japan.
  • Department of Hepato-Biliary-Pancreatic and Breast Surgery, Ehime University Graduate School of Medicine, Toon City, Ehime, Japan.
  • Division of Diagnostic Pathology, Ehime University Hospital, Toon City, Ehime, Japan.

ORCID-Profile: Sohei Kitazawa

Zitieren

APA

Iwata, M., Haraguchi, R., Kitazawa, R., Ito, C., Ogawa, K., Takada, Y., & Kitazawa, S. (2024). Reduced chemokine C‐C motif ligand 1 expression may negatively regulate colorectal cancer progression at liver metastatic sites. Journal of Cellular and Molecular Medicine. https://doi.org/10.1111/jcmm.18193

Vancouver

Iwata M, Haraguchi R, Kitazawa R, Ito C, Ogawa K, Takada Y, et al. Reduced chemokine C‐C motif ligand 1 expression may negatively regulate colorectal cancer progression at liver metastatic sites. Journal of Cellular and Molecular Medicine. 2024. doi:10.1111/jcmm.18193

BibTeX
@article{Iwata2024,
  author = {Iwata, Miku and Haraguchi, Ryuma and Kitazawa, Riko and Ito, Chihiro and Ogawa, Kohei and Takada, Yasutsugu and Kitazawa, Sohei},
  title = {Reduced chemokine C‐C motif ligand 1 expression may negatively regulate colorectal cancer progression at liver metastatic sites},
  journal = {Journal of Cellular and Molecular Medicine},
  year = {2024},
  doi = {10.1111/jcmm.18193}
}
Kostenlos starten →